Bank of New York Mellon
DFTX

Bank of New York Mellon’s Definium Therapeutics DFTX Stock Holding History

Bank of New York Mellon’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.6M Buy
777,271
+24,349
+3% +$602K 0.01% 1265
2026
Q1 		$14.2M Buy
752,922
+454,262
+152% +$7.71M ﹤0.01% 1726
2025
Q4 		$4M Buy
298,660
+69,629
+30% +$862K ﹤0.01% 2443
2025
Q3 		$2.7M Sell
229,031
-11,708
-5% -$109K ﹤0.01% 2647
2025
Q2 		$1.56M Buy
240,739
+40,542
+20% +$267K ﹤0.01% 2876
2025
Q1 		$1.17M Buy
200,197
+76
+0% +$544 ﹤0.01% 2977
2024
Q4 		$1.39M Buy
200,121
+10,338
+5% +$71.1K ﹤0.01% 2940
2024
Q3 		$1.08M Sell
189,783
-56,425
-23% -$392K ﹤0.01% 3098
2024
Q2 		$1.78M Buy
246,208
+203,216
+473% +$1.78M ﹤0.01% 2860
2024
Q1 		$404K Sell
42,992
-19,254
-31% -$110K ﹤0.01% 3652
2023
Q4 		$228K Sell
62,246
-687
-1% -$2.07K ﹤0.01% 3912
2023
Q3 		$197K Sell
62,933
-1,125
-2% -$4.62K ﹤0.01% 3962
2023
Q2 		$229K Buy
64,058
+29,782
+87% +$103K ﹤0.01% 3937
2023
Q1 		$109K Buy
34,276
+9,509
+38% +$31.6K ﹤0.01% 4060
2022
Q4 		$54.5K Buy
+24,767
New +$68.8K ﹤0.01% 4226
2022
Q3 		– Sell
-2,853
Closed -$28K – 4580
2022
Q2 		$28K Sell
2,853
-59,573
-95% -$754K ﹤0.01% 4452
2022
Q1 		$1.04M Buy
62,426
+1,117
+2% +$19.4K ﹤0.01% 3291
2021
Q4 		$1.27M Buy
61,309
+2,253
+4% +$71.9K ﹤0.01% 3252
2021
Q3 		$2.06M Buy
59,056
+8,966
+18% +$388K ﹤0.01% 2954
2021
Q2 		$2.59M Buy
+50,090
New +$2.63M ﹤0.01% 2834

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return
Swiss National Bank
Swiss National Bank Zurich, Switzerland $191B AUM 45.21% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Bank of New York Mellon's DFTX Position: Q2 2026 in Review

Bank of New York Mellon increased its Definium Therapeutics (DFTX) stake by 3.2% in Q2 2026, buying an estimated $602K and bringing the position to 777,271 shares worth $36.6M. The position accounts for 0.01% of the portfolio, ranked #1265.

Bank of New York Mellon first reported a position in DFTX in Q2 2021 and has held it in 20 quarters since. 159 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Bank of New York Mellon held 777,271 shares of Definium Therapeutics worth $36.6M as of Q2 2026.
  • Bank of New York Mellon bought 24,349 Definium Therapeutics shares in Q2 2026, an estimated $602K.
  • Definium Therapeutics made up 0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #1265 holding.
  • Bank of New York Mellon first reported a position in Definium Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • 159 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.